Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by 23andMe, Inc. 23andMe Launches New Genetic Report on Bipolar Disorder June 05, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community June 04, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting June 03, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history May 29, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results May 23, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals May 14, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME PTPI 23andMe to Report Q4 and Full Year FY2024 Financial Results May 09, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting April 24, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe announces CEO’s intention to pursue a potential take-private April 18, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 April 05, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 March 20, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago March 19, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Launches New Genetic Reports on Common Forms of Cancer March 06, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 March 05, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Reports Third Quarter Fiscal 2024 Financial Results February 07, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers GSK ME 23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 January 31, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay January 30, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe to Report FY2024 Third Quarter Financial Results January 24, 2024 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts December 19, 2023 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Reports Second Quarter Fiscal 2024 Financial Results November 08, 2023 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership November 07, 2023 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 November 06, 2023 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data October 31, 2023 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK October 30, 2023 From 23andMe, Inc. Via GlobeNewswire Tickers GSK ME 23andMe to Report FY2024 Second Quarter Financial Results October 25, 2023 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting September 27, 2023 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program September 14, 2023 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Granted New FDA Clearance to Report Additional BRCA Variants August 31, 2023 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe Reports FY2024 First Quarter Financial Results August 08, 2023 From 23andMe, Inc. Via GlobeNewswire Tickers ME 23andMe to Report FY2024 First Quarter Financial Results July 25, 2023 From 23andMe, Inc. Via GlobeNewswire Tickers ME Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.